search
Back to results

Sildenafil After the Fontan Operation (SAFO)

Primary Purpose

Hypoplastic Left Heart Syndrome, Tricuspid Atresia

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Sildenafil
Placebo
Sponsored by
Children's Hospital of Philadelphia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypoplastic Left Heart Syndrome focused on measuring Other Single Ventricle Anatomy, Hypoplastic Left Heart Syndrome, Tricuspid Atresia

Eligibility Criteria

8 Years - 40 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 8 years of age or older
  • All participants must have had Fontan completion

Exclusion Criteria:

  • Height less than 132 cm
  • Unable to participate in exercise testing due to medical restrictions or physical limitations
  • Fontan baffle obstruction or single lung physiology
  • Coarctation of the aorta or neo-aorta (BP gradient > 20 mmHg)
  • Severe ventricular dysfunction assessed qualitatively by echocardiography
  • Severe atrioventricular valvar regurgitation assessed qualitatively by echocardiography
  • Presence of electronic pacemaker
  • History of treatment with sildenafil in the six weeks prior to enrollment in study
  • Patients with severe renal impairment
  • Patients with severe hepatic impairment
  • Patients taking medications that inhibit or induce Cytochrome P450 3A4 (CYP3A4) (including grapefruit juice and St. John's Wort)
  • Patients taking alpha-blockers and nitrates
  • Parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Sildenafil, then Placebo

    Placebo, then Sildenafil

    Arm Description

    Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.

    Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks

    Outcomes

    Primary Outcome Measures

    Change From Baseline in Mean Oxygen Consumption (mL/kg/Min) at 6 Weeks
    Oxygen consumption measurements were taken at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.

    Secondary Outcome Measures

    Change From Baseline in Mean Heart Rate (Bpm) at 6 Weeks
    Heart rate was measured at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.
    Change From Baseline in Mean Respiratory Rate (Breaths/Min) at 6 Weeks
    Respiratory rate was measured at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.
    Change From Baseline in Mean Minute Ventilation (L/Min) at 6 Weeks
    Minute ventilation measurements were taken at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.

    Full Information

    First Posted
    July 25, 2007
    Last Updated
    May 4, 2015
    Sponsor
    Children's Hospital of Philadelphia
    Collaborators
    The Mark H. and Blanche M. Harrington Foundation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00507819
    Brief Title
    Sildenafil After the Fontan Operation
    Acronym
    SAFO
    Official Title
    The Sildenafil After Fontan Operation Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2007 (undefined)
    Primary Completion Date
    April 2009 (Actual)
    Study Completion Date
    July 2009 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Children's Hospital of Philadelphia
    Collaborators
    The Mark H. and Blanche M. Harrington Foundation

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation. The investigators will also evaluate echocardiographic measures of ventricular function and measure quality of life changes using two validated quality of life measures. The hypothesis is that sildenafil will result in increased exercise tolerance in patients who have had the Fontan operation as compared to placebo.
    Detailed Description
    The Fontan physiology is the end result of staged reconstruction of the heart and the major blood vessels in patients who have a single ventricle. After completion of the reconstruction, the great veins which usually bring blood back to the heart are connected directly to the pulmonary arteries, allowing blood from the body to bypass the heart and flow directly into the lungs. In this system, blood flow through the lungs is passive (not pumped) and the efficiency of flow through the cardiovascular system is related to the resistance to blood flow in the vessels of the lungs. There are two potential problems that arise in this scenario, as a result of the resistance to blood flow in the vessels of the lungs. First, the amount of blood flow returning to the heart from the lungs may not be sufficient to allow the heart to function at maximum efficiency, compromising the heart's ability to keep up with the demands of the body. Second, if the resistance to blood flow in the lungs is high, pressure may be transmitted back into the great veins themselves and secondarily into the organs of the body causing mild, or sometimes significant, organ dysfunction. Not all patients with the Fontan physiology develop these problems, but we know that even in patients without obvious problems, the ability to keep up with an increased metabolic demand, as during exercise, in compromised. Improving the efficiency of blood flow through the lungs should improve the return of blood to the heart and thereby diminish the pressure transmitted back to the vessels which passively deliver blood to the lungs. We believe that this change may manifest as diminished symptoms in those patients with known difficulties, or may allow for an increased ability to walk, run, or participate in sports in those without any overt symptoms. Most importantly, we speculate that improved efficiency of flow through the lungs, and the resulting improved cardiac output (blood flow through the body) will make patients more energetic and will make them feel better. Sildenafil is an oral medication that has been used to treat patients with pulmonary hypertension, a disease in which there is abnormally elevated pressure in the vessels of the lung. In this disease, the resistance in the lungs is abnormally high, severely limiting the ability of the heart to keep up with the demands of the body. Sildenafil lowers the resistance in the vessels of the lungs and has been shown to improve exercise performance in patients with this disease. We believe that Sildenafil may have a similar benefit for our patients after Fontan operation in whom cardiac output is also limited by resistance of the blood vessels in the lungs. In our study, we will compare the exercise capacity, echocardiographic measures of cardiac function, and the overall quality of life in patients with the Fontan before and after a six-week period of sildenafil administration. As a control, the same group of patients will take a placebo for a six-week period, also with before and after testing. We hypothesize that oral sildenafil will result in significant improvements in exercise capacity, energy levels, and echocardiographic measures of cardiac function and output in our study participants. We are hopeful that the findings of this investigation will directly help children and young adults with Fontan physiology.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypoplastic Left Heart Syndrome, Tricuspid Atresia
    Keywords
    Other Single Ventricle Anatomy, Hypoplastic Left Heart Syndrome, Tricuspid Atresia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    28 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sildenafil, then Placebo
    Arm Type
    Active Comparator
    Arm Description
    Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
    Arm Title
    Placebo, then Sildenafil
    Arm Type
    Active Comparator
    Arm Description
    Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Sildenafil
    Other Intervention Name(s)
    Revatio, Viagra
    Intervention Description
    One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    One placebo capsule will be taken by mouth three times-a-day.
    Primary Outcome Measure Information:
    Title
    Change From Baseline in Mean Oxygen Consumption (mL/kg/Min) at 6 Weeks
    Description
    Oxygen consumption measurements were taken at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.
    Time Frame
    Baseline and 6 Weeks
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in Mean Heart Rate (Bpm) at 6 Weeks
    Description
    Heart rate was measured at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.
    Time Frame
    Baseline and 6 Weeks
    Title
    Change From Baseline in Mean Respiratory Rate (Breaths/Min) at 6 Weeks
    Description
    Respiratory rate was measured at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.
    Time Frame
    Baseline and 6 Weeks
    Title
    Change From Baseline in Mean Minute Ventilation (L/Min) at 6 Weeks
    Description
    Minute ventilation measurements were taken at peak exercise. Subjects were exercised to maximal volition with an electronically braked cycle ergometer. The protocol consisted of 3 minutes of pedaling in an unloaded state followed by a ramp increase in work rate (watts) to maximal exercise. Metabolic and ventilatory data were obtained throughout the exercise study and for the first 2 minutes of recovery on a breath-by-breath basis with a metabolic cart.
    Time Frame
    Baseline and 6 Weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    8 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 8 years of age or older All participants must have had Fontan completion Exclusion Criteria: Height less than 132 cm Unable to participate in exercise testing due to medical restrictions or physical limitations Fontan baffle obstruction or single lung physiology Coarctation of the aorta or neo-aorta (BP gradient > 20 mmHg) Severe ventricular dysfunction assessed qualitatively by echocardiography Severe atrioventricular valvar regurgitation assessed qualitatively by echocardiography Presence of electronic pacemaker History of treatment with sildenafil in the six weeks prior to enrollment in study Patients with severe renal impairment Patients with severe hepatic impairment Patients taking medications that inhibit or induce Cytochrome P450 3A4 (CYP3A4) (including grapefruit juice and St. John's Wort) Patients taking alpha-blockers and nitrates Parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jack Rychik, MD
    Organizational Affiliation
    Children's Hospital of Philadelphia
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    21382896
    Citation
    Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011 Mar 22;123(11):1185-93. doi: 10.1161/CIRCULATIONAHA.110.981746. Epub 2011 Mar 7.
    Results Reference
    derived

    Learn more about this trial

    Sildenafil After the Fontan Operation

    We'll reach out to this number within 24 hrs